Pediatric Expanded Access Program-Oral Solution (0831-908)

Merck Sharp & Dohme LLC

Overview

Monitor the safety and tolerability of efavirenz oral solution in combination with Antiretroviral Therapy for the treatment of patients age 3 to 16 years who have failed therapy or who are intolerant to their current therapy. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

HIV Infections

Interventions

MK0831DRUG

Eligibility

Sex: ALLMin age: 3 YearsMax age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Not tolerating current ART regime laboratory status is stable * Able to take oral liquid medications but have difficulty swallowing capsules * Weigh at least 10 kg (22 lbs) Exclusion Criteria: * Has had more than 2 episodes of moderate to severe diarrhea or vomiting lasting more than 4 days within 3 months prior to taking study drug * Have taken another investigational drug 30 days before starting this study * Have a history of drug or alcohol abuse

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.